Wave Life Sciences (NASDAQ:WVE) Stock Upgrade
Wave Life Sciences (NASDAQ:WVE) shares were boosted by BidaskScore to a “Buy” rating in a research note revealed on Tuesday, 3 December.
The stock increased 3.70% or $1.26 during the last trading session, reaching $35.36. About 221,859 shares traded or 5.92% up from the average. Wave Life Sciences Ltd. (NASDAQ:WVE) has declined 44.46% since December 5, 2018 and is downtrending. It has underperformed by 44.46% the S&P500.
Analysts await Wave Life Sciences Ltd. (NASDAQ:WVE) to report earnings on March, 6. They expect $-1.48 earnings per share, down 14.73 % or $0.19 from last year’s $-1.29 per share. After $-1.48 actual earnings per share reported by Wave Life Sciences Ltd. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.
WAVE Life Sciences Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company has market cap of $1.21 billion. The firm is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It currently has negative earnings. The Company’s advanced therapeutic programs are in HuntingtonÂ’s disease, Duchenne muscular dystrophy , and inflammatory bowel disease (IBD).
More notable recent Wave Life Sciences Ltd. (NASDAQ:WVE) news were published by: Globenewswire.com which released: “Wave Life Sciences Expands Board of Directors with Three New Appointments – GlobeNewswire” on September 05, 2019, also Finance.Yahoo.com with their article: “Is Scholastic Corp (SCHL) A Good Stock To Buy? – Yahoo Finance” published on June 29, 2019, Seekingalpha.com published: “Wave’s suvodirsen Fast Track’d for DMD; shares up 7% – Seeking Alpha” on September 16, 2019. More interesting news about Wave Life Sciences Ltd. (NASDAQ:WVE) were released by: Globenewswire.com and their article: “Wave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference – GlobeNewswire” published on March 25, 2019 as well as Globenewswire.com‘s news article titled: “Wave Life Sciences Provides Timing Update on PRECISION-HD Clinical Programs – GlobeNewswire” with publication date: April 10, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.